Sandu Pharmaceuticals Ltd Financial Ratios
SANDUPHQ · Healthcare · Current price ₹35.74
P/E ratio
19.5x
P/B ratio
1.0x
ROE
4.0%
ROCE
6.3%
Debt / Equity
0.01
Dividend yield
2.6%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 19.5x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 1.0x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 4.0% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 6.3% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.01 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Sandu Pharmaceuticals Ltd's latest numbers.
Sandu Pharmaceuticals Ltd profitability
Sandu Pharmaceuticals Ltd generates a return on equity of 4.0% and a return on capital employed of 6.3%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.01 and a P/E of 19.5x, Sandu Pharmaceuticals Ltd is conservatively financed. Our overall business-quality score for the company is 3.8 / 10.
Understand the ratios
More on Sandu Pharmaceuticals Ltd
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.